A Risk Factor for Atherosclerosis: Triglyceride-rich Lipoproteins

Advances in Internal Medicine

Volumn 47, Issue , 2001, Pages 111-136

  Malloy, Mary J ^a,b   Kane, John P ^a,b  

^a Cardiovascular Research Institute   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; NICOTINIC ACID; TRIACYLGLYCEROL;

CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DRUG COMBINATION; GENETICS; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOLOGY; REVIEW; RISK FACTOR;

ANTILIPEMIC AGENTS; CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS; DRUG THERAPY, COMBINATION; GEMFIBROZIL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPOPROTEINS; MULTIVARIATE ANALYSIS; NIACIN; PHENOTYPE; RISK FACTORS; TRIGLYCERIDES;

EID: 0035756399     PISSN: 00652822     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (88)

1. Goftnan JO, Blazier F, Tamplin A, et al: Lipoproteins, coronary heart disease, and atherosclerosis. Physiol Rev 34:589-607, 1954.
2. Albrink MJ, Mann EB: Serum triglycérides in coronary artery disease. Arch Intern Med 103:4-8, 1959.
3. Castelli WP: Epidemiology of triglycérides: A view from Framingham. Am J Cardiol 70:3H-9H, 1992.
4. Criqui MH, Heiss G, Cohn R, et al: Plasma triglycéride level and mortality from coronary heart disease. N Engl J Med 328:1220-1225, 1993.
5. Assmann G, Schulte H, von Eckardstein A: Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 77:1179-1184, 1996.
6. Bainton D, Miller NE, Bolton CH, et al: Plasma triglycéride and high density lipoprotein cholesterol as predictors of ischaemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Br Heart J 68:60-66, 1992.
7. Stampfer MJ, Krauss RM, Ma J, et al: A prospective study of triglycéride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 276:882-888, 1996.
8. Austin MA, Hokanson JE, Edwards KL: Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81:7B-12B, 1998.
9. Austin MA: Epidemiology of hypertriglyceridemia and cardiovascular disease. Am J Cardiol 83:13F-16F, 1999.
10. Jeppesen J, Hein HO, Suadicani P, et al: Triglycéride concentration and ischémie heart disease: An eight-year follow-up in the Copenhagen Male Study. [Published erratum appears in Circulation 97:1995,1998.] Circulation 97:1029-1036, 1998.
11. Miller M, Seidler A, Moalemi A, et al: Normal triglycéride levels and coronary artery disease events: The Baltimore Coronary Observational Long-Term Study, f Am Coll Cardiol 31:1252-1257, 1998.
12. Austin MA, McKnight B, Edwards KL, et al: Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study. Circulation 101:2777-2782, 2000.
13. Bissett JK, Wyeth RP, Matts JP, et al: Plasma lipid concentrations and subsequent coronary occlusion after a first myocardial infarction. The POSCH Group. Am f Med Sei 305:139-144, 1993.
14. Malloy MJ, Kane JP: Aggressive medical therapy for the prevention and treatment of coronary artery disease, in Schrier RW, Abboud FM, Baxter JD, et al (eds): Advances in Internal Medicine. St Louis, Mosby, 1997, pp 1-38.
15. Kane JP, Havel RJ: Disorders of the biogenesis and secretion of lipoproteins containing the B-apolipoproteins, in Scriver CR, Beaudet al, Valle D, et al (eds): The Metabolic Basis of Inherited Disease. New York, McGraw-Hill, 2001, pp 2717-2752.
16. Fisher EA, Zhou M, Mitchell DM, et al: The degradation of apolipoprotein B100 is mediated by the ubiquitin-proteasome pathway and involves heat shock protein 70. /Biol Chem 272:20427-20434, 1997.
17. Ginsberg HN: Insulin resistance and cardiovascular disease. / Clin Invest 106:453-458, 2000.
18. Lewis GF: Fatty acid regulation of very low density lipoprotein production. Curr Opin Lipidol 8:146-153, 1997.
19. Havel RJ, Kane JP: Structure and metabolism of plasma lipoproteins, in Scriver CR, Beaudet al, Valle D, et al (eds): The Metabolic Basis of Inherited Disease. New York, McGraw-Hill, 2001, pp 2705-2716.
20. Rapp JH, Harris HW, Hamilton RL, et al: Particle size distribution of lipoproteins from human atherosclerotic plaque: A preliminary report. / Vase Surg 9:81-88, 1989.
21. Rapp JH, Lespine A, Hamilton RL, et al: Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb 14:17671774, 1994.
22. Bradley WA, Gianturco SH: Triglyceride-rich lipoproteins and atherosclerosis: Pathophysiological considerations. / Intern Med Suppl 736: 33-39, 1994.
23. Phillips NR, Waters D, Havel RJ: Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 88:2762-2770, 1993.
24. Havel RJ: Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol 5:102-109, 1994.
25. Krauss RM, Lindgren FT, Williams PT, et al: Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet 2:62-66, 1987.
26. Blankenhorn DH, Alaupovic P, Wickham E, et al: Prediction of angiographie change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Circulation 81:470-476, 1990.
27. Alaupovic P, Mack WJ, Knight-Gibson C, et al: The role of triglyceriderich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vase Biol 17:715-722, 1997.
28. Azen SP, Mack WJ, Cashin-Hemphill L, et al: Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation 93:34-41, 1996.
29. Mack WJ, Krauss RM, Hodis HN: Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographie progression. Arterioscler Thromb Vase Biol 16:697-704, 1996.
30. Hodis HN, Mack WJ, Dunn M, et al: Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation 95:2022-2026, 1997.
31. Karpe F, Steiner G, Uffelman K, et al: Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 106:83-97, 1997.
32. Patsch JR, Miesenböck G, Hopferwieser T, et al: Relation of triglycéride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 12:1336-1345, 1992.
33. Sharrett AR, Chambless LE, Heiss G, et al: Association of postprandial triglycéride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vase Biol 15:2122-2129, 1995.
34. Masuoka H, Ishikura K, Kamei S, et al: Predictive value of remnantlike particles cholesterol/high-density lipoprotein cholesterol ratio as a new indicator of coronary artery disease. Am Heart J 136:226-230, 1998.
35. Mietus-Snyder M, Malloy MJ: Endothelial dysfunction occurs in children with two genetic hyperlipidernias: Improvement with antioxidant vitamin therapy. / Pediatr 133:35-40, 1998.
36. Vogel RA, Corretti MC, Plotnick GD: Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol 79:350-354, 1997.
37. Plotnick GD, Corretti MC, Vogel RA: Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal. JAMA 278:1682-1686, 1997.
38. Chadarevian R, Bruckert E, Dejager S, et al: Relationship between triglycérides and factor VIIc and plasminogen activator inhibitor type-1: Lack of threshold value. Thromb Res 96:175-182, 1999.
39. Eriksson P, Nilsson L, Karpe F, et al: Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vase Biol 18:20-26, 1998.
40. Otvos J: Measurement of triglyceride-rich lipoproteins by nuclear magnetic resonance spectroscopy. Clin Cardiol 22:1121-27, 1999.
41. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972.
42. Senti M, Pedro-Botet J, Noguis X, et al: Influence of intermediatedensity lipoproteins on the accuracy of the Friedewald formula. Clin Chem 37:1394-1397, 1991.
43. Frost PH, Havel RJ: Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol 81:26B-31B, 1998.
44. Brunzell JD, Deeb SS: Familial lipoprotein lipase deficiency, apo C-II deficiency, and hepatic lipase deficiency, in Scriver CR, Beaudet al, Valle D, et al (eds): The Metabolie and Molecular Bases of Inherited Disease. New York, McGraw-Hill, 2001, pp 2789-2816.
45. Wittrup HH, Tybjaerg-Hansen A, Steffensen R, et al: Mutations in the lipoprotein lipase gene associated with ischémie heart disease in men. The Copenhagen City Heart Study. Arterioscler Thromb Vase Biol 19:1535-1540, 1999.
46. Nordestgaard EG, Abildgaard S, Wittrup HH, et al: Heterozygous lipoprotein lipase deficiency: Frequency in the general population, effect on plasma lipid levels, and risk of ischémie heart disease. Circulation 96:1737-1744, 1997.
47. Wittrup HH, Tybjaerg-Hansen A, Abildgaard S, et al: A common substitution (Asn29lSer) in lipoprotein lipase is associated with increased risk of ischémie heart disease. / Clin Invest 99:1606-1613, 1997.
48. Mahley RW, Rail SC: Type III hyperlipoproteinemia (dysbetalipoproteinemia): The role of apolipoprotein E in normal and abnormal lipoprotein metabolism, in Scriver CR, Beaudet al, Valle D, et al (eds): The Metabolic Basis of Inherited Disease. New York, McGraw-Hill, 2001, pp 2835-2862.
49. Auwerx JH, Marzetta ÇA, Hokanson JE, et al: Large buoyant LDL-like particles in hepatic lipase deficiency. Arteriosclerosis 9:319-325,1989.
50. Zambon A, Deeb SS, Hokanson JE, et al: Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol. Arterioscler Thromb Vase Biol 18:1723-1729, 1998.
51. Nie L, Wang J, Clark LT, et al: Body mass index and hepatic lipase gene (LIPC) polymorphism jointly influence postheparin plasma hepatic lipase activity. J Lipid Res 39:1127-1130, 1998.
52. Courts JMW, Janssen RGJH, van Greevenbroek MMJ, et al: Identification of TNFRSF1B as a novel modifier gene in familial combined hyperlipidemia. Hum Mol Genet 9:2067-2074, 2000.
53. Aouizerat BE, Allayee H, Bodnar J, et al: Novel genes for familial combined hyperlipidemia. Curr Opin Lipidol 10:113-122, 1999.
54. Hokanson JE: Functional variants in the lipoprotein lipase gene and risk of cardiovascular disease. Curr Opin Lipidol 10:393-399, 1999.
55. Yang WS, Nevin DN, Iwasaki L, et al: Regulatory mutations in the human lipoprotein lipase gene in patients with familial combined hyperlipidemia and coronary artery disease. /Lipid Res 37:2627-2637, 1996.
56. Chen GC, Liu W, Duchateau P, et al: Conformational differences in human apolipoprotein B-100 among subspecies of low density lipoproteins (LDL). Association of altered proteolytic accessibility with decreased receptor binding of LDL subspecies from hypertriglyceridemic subjects. / Biol Chem 269:29121-29128, 1994.
57. Austin MA, Hokanson JE, Brunzell JD: Characterization of low-density lipoprotein subclasses: Methodologie approaches and clinical relevance. Curr Opin Lipidol 5:395-403, 1994.
58. Feingold KR, Grunfeld C, Pang M, et al: LDL subclass phenotypes and triglycéride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 12:1496-1502, 1992.
59. Stewart MW, Laker MF, Dyer RG, et al: Lipoprotein compositional abnormalities and insulin resistance in type II diabetic patients with mild hyperlipidemia. Arterioscler Thromb 13:1046-1052, 1993.
60. Fujimoto WY, Abbate SL, Kahn SE, et al: The visceral adiposity syndrome in Japanese-American men. Obes Res 93:189-199, 1994.
61. de Graaf J, Hak-Lemmers HL, Hectors MP, et al: Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subtraction in healthy subjects. Arterioscler Thromb 11:298-306, 1991.
62. Tribble DL, Holl LG, Wood PD, et al: Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 93:189-199, 1992.
63. Reaven GM: Role of insulin resistance in human disease (syndrome X): An expanded definition. Annu Rev Med 44:121-131, 1993.
64. Rändle PJ, Newsholme EA, Garland PB: Regulation of glucose uptake by muscle. 8. Effects of fatty acids, ketone bodies and pyruvate, and of alloxan-diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles. Biochem J 93:652-665, 1964.
65. Boden G: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. [Published erratum appears in Diabetes 46:536, 1997.] Diabetes 46:3-10, 1997.
66. Shulman GI: Cellular mechanisms of insulin resistance. / Clin Invest 106:171-176, 2000.
67. Kahn BB, Flier JS: Obesity and insulin resistance. / Clin Invest 106:473-481, 2000.
68. Barroso I, Gurnell M, Crowley VE, et al: Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402:880-883, 1999.
69. Willson TM, Brown PJ, Sternbach DD, et al: The PPARs: From orphan receptors to drug discovery. J Med Chem 43:527-550, 2000.
70. Mukherjee R, Davies PJ, Crombie DL, et al: Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 386:407-410, 1997.
71. Steppan CM, Bailey ST, Bhat S, et al: The hormone resistin links obesity to diabetes. Nature 409:307-312, 2001.
72. Yamauchi T, Kamon J, Waki H, et al: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001.
73. Hotta K, Funahashi T, Arita Y, et al: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vase Biol 20:1595-1599, 2000.
74. Maeda N, Takahashi M, Funahashi T, et al: PPAR"/ ligands increase expression and plasma concentrations of adiponectin, an adiposederived protein. Diabetes 50:2094-2099, 2001.
75. Li XN, Grenett HE, Benza RL, et al: Genotype-specific transcriptional regulation of PAI-1 expression by hypertriglyceridemic VLDL and Lp(a) in cultured human endothelial cells. Arterioscler Thromb Vase Biol 17:3215-3223, 1997.
76. Malloy MJ, Kane JP: Agents used in hyperlipidemia, in Katzung B (ed): Basic and Clinical Pharmacology. Norwalk, Conn, Appleton and Lange, 2001, pp 581-595.
77. Stein EA, Lane M, Laskarzewski P: Comparison of statins in hypertriglyceridemia. Am J Cardiol 81:66B-69B, 1998.
78. Vega GL, Grundy SM: Effect of statins on metabolism of apo-Bcontaining lipoproteins in hypertriglyceridemic men. Am J Cardiol 81:36B-42B, 1998.
79. Drmanac S, Heilbron DC, Pullinger CR, et al: Elevated baseline triglycéride levels modulate effects of HMGCoA reductase inhibitors on plasma lipoproteins. / Cardiovasc Pharmacol Ther 6:47-56, 2001.
80. Frick MH, Elo O, Haapa K, et al: Helsinki Heart Study: Primaryprevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl ] Med 317:1237-1245, 1987.
81. Manninen V, Elo MO, Frick MH, et al: Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 260:641-651, 1988.
82. Manninen V, Tenkanen L, Koskinen P, et al: Joint effects of serum triglycéride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulatior 85:37-45, 1992.
83. De Faire U, Ericsson CG, Grip L, et al: Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Invervention Trial (BECAIT). Eur Heart /14:S37-S42, 1996.
84. Goldbourt U, Brunner D, Behar S, et al: Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study. EurHearf/19:H42-H47, 1998.
85. Cashin-Hemphill L, Mack WJ, Pogoda JM, et al: Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 264:3013-3017, 1990.
86. Zambon A, Hokanson JE, Brown BG, et al: Evidence for a new pathophysiological mechanism for coronary artery disease regression: Hepatic lipase-mediated changes in LDL density. Circulation 99:19591964, 1999.
87. Brown BG, Zambon A, Poulin D, et al: Use of niacin, statins, and resins in patients with combined hyperlipidemia. Am J Cardiol 81:52B-59B, 1998.
88. Rubins HB, Robins SJ, Collins D, et al: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341:410-418, 1999.